Cancer Vaccines Market by Type (Preventive Vaccine and Therapeutic Vaccine), by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccine, and Whole-cell Cancer Vaccines), by Indication (Prostate Cancer, Cervical Cancer, and Others), and by End-user (Adult and Pediatric Vaccine) - Global Opportunity Analysis and Industry Forecast 2022-2030

Market Definition:

The Cancer Vaccines Market was valued at USD 4.32 billion in 2021 and is predicted to reach USD 12.17 billion by 2030 with a CAGR of 12.2% from 2022-2030.

Cancer vaccines are a biological response modifier that stimulates the body’s immune system to fight against cancer. Currently, preventive and therapeutic vaccines are gaining momentum in the global market. Several vaccines have been approved in the past few years to prevent HPV infection, prostate, and other cancers. Besides, the highly crowded pipeline where vaccines are showcasing encouraging success in clinical trials across a wide range of cancers indicates a strong future for the market. Also, with continuous R&D activities in this field, researchers have developed other improved platforms for vaccine development, such as personalized neoantigen cancer vaccines, mRNA vaccines, stem cells, and others. However, these are in the early stages of development but represent a huge potential in the market. 

Market Dynamics and Trends:

A surge in the cases of HPV infections that leads to cervical cancer is expected to drive the demand for these vaccines. According to the World Health Organization (WHO), there were ~ 604 000 new cases and 342 000 deaths due to cervical cancer in 2020 globally. Among this, ~90% of new cases & deaths belonged to low- and middle-income nations. Also, new product development, extended approval to approved vaccines, and a rise in government initiatives are the other factors driving the growth.

For instance, the Health Ministry of Japan resumed recommending HPV vaccines to girls aged 12 to 16 years in March 2022. In June 2022, China’s NMPA approved a two-dose schedule for GSK’s HPV vaccine Cervarix in the girls aged 9-14 years for preventing cervical tumor. In addition, technological advancement in healthcare sectors, such as early diagnosis and vaccine delivery platforms including Liposomal Delivery Systems and Virosomes is further accelerating the market growth. Moreover, unhealthy dietary habits and consumption of tobacco that leads to tumor also increase the demand for these vaccines.

However, the presence of alternative therapies such as acupuncture, aromatherapy and longer timelines in manufacturing vaccines are among a few factors restraining the market growth. Conversely, approval of a new type of vaccines including TheraCys, TICE, and PROVENGE is projected to create new avenues for the market in the forecast period. 

Market Segmentations and Scope of the Study:

The cancer vaccines market is segmented based on technology, type, indication, end-user, and geography. Based on technology, the market is classified into Dendritic Cells (DC), Recombinant, Antigen/Adjuvant, Viral Vector & DNA, and Whole-cell Cancer Vaccines. Based on type, the market is bifurcated into preventive and therapeutic vaccines. Based on indication, the market is analyzed across prostate, cervical, and others. Based on end-user, the market is divided into adult and pediatric vaccines. Geographic breakdown and analysis of each of the aforesaid segments include regions comprising of North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis:

North America holds maximum share in the global market and is expected to continue its dominance throughout the forecast period. This is attributed to a rise in number of hospitals & diagnostic centers equipped with advanced medical facilities & technologies and high prevalence of disease in this region. As per the American Cancer Society, ~1.9 million new cases of cancer are expected to be diagnosed, and ~609,360 deaths are projected in 2022 in the U.S. Additionally, rise in the leading manufacturers are focusing on expanding their geographical presence that further boost the regional market. For instance, In June 2020, UbiVac collaborated with Bristol Myers to evaluate tolerability, efficacy and safety of its DPV-001 cancer vaccine product with Bristol’s anti-OX40 and Opdivo. This joint effort tests that this combination would support anticancer immunity in advanced triple negative breast cancer. 

On the other hand, Asia-Pacific is expected to show a steady rise owing to an increase in the geriatric population suffering from cancer, such as gastric & prostate cancer. For instance, in 2021, according to BMC, the incidence of gastric cancer was 64 per 100,000 among the population aged 50–59 years and 143 per 100,000 in people aged 60–69 years in China.  Also, development of the R&D sector in the field of oncology with an advancement of plasma therapies to treat this disease in countries such as China and India is further propelling the regional growth. For instance, in July 2021, the Chinese health authority NMPA’s Center for Drug Evaluation released new guidance on oncology R&D that directs the drug makers to focus on a patient-centric R&D approach, driving clinical trials and focusing research around areas of unmet needs.

Competitive Landscape:

Cancer vaccines market is comprised of various market players namely GlaxoSmithKline Plc., CSL Limited, Pfizer Inc., Bristol-Myers Squibb, AstraZeneca Plc., Sanofi, Vaccinogen Inc., The Sanpower Group, Moderna Inc., Merck & Co., Inc., and Astellas Pharma Inc. These manufacturers are actively involved in several strategies such as agreements and business expansions to further enhance their product portfolio and geographical reach.

For instance, in October 2022, Merck opted to jointly develop and market a personalized mRNA vaccine along with Moderna. Similarly, in November 2020, Moderna Inc. announced an expansion cohort of its ongoing Phase 1 study for its personalized cancer vaccine (PCV) mRNA-4157 in combination with Keytruda from Merck. The vaccine along with Keytruda is well tolerated at all dose levels and showed positive results for HPV(-) HNSCC patients, thereby expanding its application for Head and Neck Squamous Cell Carcinoma patients.

KEY BENEFITS:

• The cancer vaccines market report provides the quantitative analysis of the current market and estimations through 2022-2030 that assists in identifying the prevailing market opportunities to capitalize on.

• The study comprises a deep dive analysis of the cancer vaccines market trend including the current and future trends for depicting the prevalent investment pockets in the market.

• The information related to key drivers, restraints and opportunities and their impact on the cancer vaccines market is provided in the report.

• The competitive analysis of the market players along with their market share in the cancer vaccines market

• The SWOT analysis and Porters Five Forces model is elaborated in the study.

• Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

KEY MARKET SEGMENTS:

By Technology

• Dendritic Cells (DC) Cancer Vaccines

• Recombinant Cancer Vaccines

• Antigen/Adjuvent Cancer Vaccines

• Viral Vector and DNA Cancer Vaccines

• Whole-cell Cancer Vaccines

By Type

• Preventive Vaccine

• Therapeutic Vaccine

By Indication

• Prostate Cancer

• Cervical Cancer

• Others

By End-user

• Adult Vaccines

• Pediatric Vaccine

By Geography

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Rest of Europe

• Asia-Pacific

  • China

  • India

  • Japan

  • Australia

  • Rest of Asia-Pacific

• RoW

  • UAE

  • Saudi Arabia

  • South Africa

  • Brazil

  • Remaining Countries